Other languages Immunotech Biopharm Ltd

Equities

6978

KYG4721A1004

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-24 am EDT			5-day change	1st Jan Change
3.06 ^HKD	+2.00%		-4.38%	-38.80%

Mar. 29	Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	MT
Mar. 28	Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	Mar. 29
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug	Feb. 19
Immunotech Biopharm Receives an Approval of the Investigational New Drug Application for Phase I Clinical Trial from the Centre for Drug Evaluation of the National Medical Products Administration for the aT19 Injection	Feb. 19
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection	Jan. 03
Immunotech Biopharm Ltd Completes the First Patient Enrolment for its Phase I Clinical Trial for the Denocabtagene Ciloleucel Injection	Nov. 07
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27
Immunotech Biopharm Ltd Announces Board Changes	23-08-27
Immunotech Biopharm Ltd Announces Director Changes	23-03-26
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24
Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration	23-03-21
Immunotech Biopharm Ltd. Receives Acceptance Notice for the Investigational New Drug Application for the Denocabtagene Ciloleucel Injection	22-12-28
Immunotech Biopharm Sees $19.6 Million H1 Loss	22-09-26
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25
Immunotech Biopharm Ltd. Submittes the Communication Meeting Application of New Drug Clinical Trial for the Company's RC19D2 Injection Product	22-02-03
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase I Clinical Trial for 6B11-OCIK Injection	22-01-30
Immunotech Biopharm : H1 Loss Narrows Amid Absence of $5.4 Million Listing Costs	21-09-21
Immunotech Biopharm Ltd. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2021	21-08-23
Immunotech Biopharm : Research on Ovarian Cancer Therapy Published in Medical Journal	21-08-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immunotech Biopharm Ltd

Equities

6978

KYG4721A1004

Other languages

Filters